ArticleTranslational oncology2016

Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma.

Jinhyun Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.